IP waiver won’t solve vaccine problems, warn experts

A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization (WTO) failing to reach consensus.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Orrick lands five-member M&A team in Paris

18 May 2026 A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.

Americas

AbbVie’s trade secret suit against a Chinese rival gets green light

18 May 2026 A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.

Americas

WATCH: Kymera Therapeutics’ Sylvia Yip on in-house leadership

18 May 2026 LSIPR’s senior reporter Marisa Woutersen speaks with the director of IP at Kymera Therapeutics about the realities of in-house IP leadership and the growing challenge of “fast followers” in biotech.

More features

Orrick lands five-member M&A team in Paris

AbbVie’s trade secret suit against a Chinese rival gets green light

WATCH: Kymera Therapeutics’ Sylvia Yip on in-house leadership

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

Blank Rome adds to growing team with patent agent from MBHB

BMS signs $15.2bn deal with China’s top pharma company

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

IP waiver won’t solve vaccine problems, warn experts

More on this story

Editor's picks

Editor's picks

More features